Tiziana Life Sciences (TLSA) Competitors $0.89 +0.08 (+9.88%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLSA vs. AKBA, PRTC, SAGE, MNMD, KROS, CRMD, TYRA, PGEN, MAZE, and ZVRAShould you be buying Tiziana Life Sciences stock or one of its competitors? The main competitors of Tiziana Life Sciences include Akebia Therapeutics (AKBA), PureTech Health (PRTC), Sage Therapeutics (SAGE), Mind Medicine (MindMed) (MNMD), Keros Therapeutics (KROS), CorMedix (CRMD), Tyra Biosciences (TYRA), Precigen (PGEN), Maze Therapeutics (MAZE), and Zevra Therapeutics (ZVRA). These companies are all part of the "pharmaceutical products" industry. Tiziana Life Sciences vs. Akebia Therapeutics PureTech Health Sage Therapeutics Mind Medicine (MindMed) Keros Therapeutics CorMedix Tyra Biosciences Precigen Maze Therapeutics Zevra Therapeutics Tiziana Life Sciences (NASDAQ:TLSA) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, community ranking, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations. Which has more risk and volatility, TLSA or AKBA? Tiziana Life Sciences has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Does the media favor TLSA or AKBA? In the previous week, Akebia Therapeutics had 2 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 2 mentions for Akebia Therapeutics and 0 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 1.89 beat Akebia Therapeutics' score of 0.98 indicating that Tiziana Life Sciences is being referred to more favorably in the media. Company Overall Sentiment Tiziana Life Sciences Very Positive Akebia Therapeutics Positive Which has stronger valuation & earnings, TLSA or AKBA? Tiziana Life Sciences has higher earnings, but lower revenue than Akebia Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTiziana Life SciencesN/AN/A-$17.69MN/AN/AAkebia Therapeutics$160.18M2.80-$51.92M-$0.33-5.76 Do analysts prefer TLSA or AKBA? Akebia Therapeutics has a consensus price target of $6.50, suggesting a potential upside of 242.11%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Akebia Therapeutics is more favorable than Tiziana Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Akebia Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is TLSA or AKBA more profitable? Tiziana Life Sciences has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -27.07%. Company Net Margins Return on Equity Return on Assets Tiziana Life SciencesN/A N/A N/A Akebia Therapeutics -27.07%N/A -20.57% Does the MarketBeat Community prefer TLSA or AKBA? Akebia Therapeutics received 324 more outperform votes than Tiziana Life Sciences when rated by MarketBeat users. However, 63.58% of users gave Tiziana Life Sciences an outperform vote while only 63.16% of users gave Akebia Therapeutics an outperform vote. CompanyUnderperformOutperformTiziana Life SciencesOutperform Votes9663.58% Underperform Votes5536.42% Akebia TherapeuticsOutperform Votes42063.16% Underperform Votes24536.84% Do insiders and institutionals hold more shares of TLSA or AKBA? 33.9% of Akebia Therapeutics shares are owned by institutional investors. 39.8% of Tiziana Life Sciences shares are owned by company insiders. Comparatively, 4.1% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryAkebia Therapeutics beats Tiziana Life Sciences on 8 of the 14 factors compared between the two stocks. Remove Ads Get Tiziana Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLSA vs. The Competition Export to ExcelMetricTiziana Life SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$104.00M$6.26B$5.29B$7.36BDividend YieldN/A3.24%5.11%4.32%P/E RatioN/A6.7221.6917.68Price / SalesN/A223.16371.6292.88Price / CashN/A65.6738.1534.64Price / Book17.805.776.373.94Net Income-$17.69M$142.23M$3.20B$247.45M7 Day Performance3.49%2.72%1.67%0.48%1 Month Performance-43.31%-14.04%-9.49%-7.08%1 Year Performance53.74%-12.31%9.59%-0.35% Tiziana Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLSATiziana Life Sciences1.2874 of 5 stars$0.89+9.9%N/A+62.0%$104.00MN/A0.008Positive NewsAKBAAkebia Therapeutics3.4764 of 5 stars$1.77flat$6.50+267.2%+36.0%$418.13M$160.18M-7.70430Gap DownPRTCPureTech Health2.8093 of 5 stars$17.30flat$45.00+160.1%-33.9%$415.53M$3.33M0.00100Upcoming EarningsShort Interest ↓High Trading VolumeSAGESage Therapeutics3.7587 of 5 stars$6.66-2.9%$8.81+32.3%-50.8%$409.46M$41.24M-1.01690Gap DownMNMDMind Medicine (MindMed)1.8836 of 5 stars$5.43flat$25.11+362.5%-42.7%$409.25MN/A-2.4040Analyst RevisionNews CoverageGap DownKROSKeros Therapeutics3.4535 of 5 stars$9.98flat$42.33+324.2%-77.3%$404.81M$3.55M-1.92100Insider TradeHigh Trading VolumeCRMDCorMedix2.7687 of 5 stars$6.07+3.6%$15.14+149.5%+37.5%$395.66M$43.47M-7.4930Gap DownTYRATyra Biosciences2.2202 of 5 stars$7.38-4.7%$30.83+317.8%-41.3%$391.80MN/A-4.5820Positive NewsGap DownPGENPrecigen3.4807 of 5 stars$1.33+7.3%$7.00+426.3%+2.9%$391.08M$3.93M-2.42190Gap DownMAZEMaze TherapeuticsN/A$8.92-1.7%$25.67+187.7%N/A$390.66M$167.50M0.00121ZVRAZevra Therapeutics2.4327 of 5 stars$7.05+0.1%$22.29+216.1%+45.5%$381.52M$23.61M-3.5820Positive News Remove Ads Related Companies and Tools Related Companies AKBA Competitors PRTC Competitors SAGE Competitors MNMD Competitors KROS Competitors CRMD Competitors TYRA Competitors PGEN Competitors MAZE Competitors ZVRA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLSA) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredIf Gold Is ‘Stalling,’ Why Are Banks Hoarding Billions In Secret?Prosperity was something every American family could build, protect, and pass down. Because that's what legacy...Colonial Metals | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredCould this be my downfall?I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tiziana Life Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Tiziana Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TLSA Stock Free TLSA Stock Alerts